Business Context and Reporting Period
This Form 8-K is a current report filed by Aeglea BioTherapeutics, Inc. (not Spyre Therapeutics, Inc.) on March 6, 2019. The registrant is a Delaware corporation and an emerging growth company. The report details a specific corporate governance event regarding executive leadership.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and appointment details.
Material Changes
The primary material change reported is the appointment of Dr. Leslie Sloan as Chief Operating Officer (COO), effective March 6, 2019. Dr. Sloan previously served as the company's Vice President of Operations since August 2017.
Management Commentary and Compensation
In connection with the COO appointment, the Board of Directors approved the following compensatory arrangements for Dr. Sloan:
- Base Salary: Increased to $355,000 per year.
- Annual Target Bonus: 40% of base salary.
- Stock Options: Granted an option to purchase 36,000 shares of common stock at an exercise price of $8.06 per share.
- Vesting Schedule: Options vest in equal monthly installments over four years, subject to continued service.
- Agreements: Standard indemnification and change of control severance agreements were executed.
Dr. Sloan brings prior experience from Ipsen Bioscience Inc. (including roles as President and VP of R&D) and Pfizer.
Investor Verification Checklist
- Verify the exact vesting terms and exercise price of the 36,000 stock options granted to the new COO.
- Review the referenced Exhibits 10.1 and 10.7 in the 2018 Form 10-K for details on the indemnification and severance agreements.
- Confirm the impact of the new executive compensation on the company's future cash burn rate, given the biopharmaceutical sector's typical capital intensity.
- Note the discrepancy between the requested company name (Spyre Therapeutics) and the actual registrant (Aeglea BioTherapeutics).